Osteoarthritis (OA) affects more than 33 million adults in the United States and remains one of the most stubborn challenges in musculoskeletal medicine. The disease gradually erodes cartilage, causing pain, stiffness, and disability, yet no FDA-approved therapy can halt or reverse this degeneration. RNA-based therapeutics have emerged as a promising strategy, but they face a fundamental obstacle: getting the therapy into the specific cartilage lesions where degeneration is actively occurring.
Researchers at Mass General Brigham have now developed a solution that brings precision targeting to joint therapy. In a study published in Nature Nanotechnology, titled “A disease-severity-responsive nanoparticle enables potent ghrelin mRNA therapy in osteoarthritis,” co-senior authors Nitin Joshi, PhD, and Jingjing Gao, PhD, along with lead author Mahima Dewani, PhD, describe a nanoparticle platform that can sense where cartilage is damaged via biochemical signals—and deliver mRNA therapy directly to those regions.
The team engineered an anionic nanoparticle system using a strategy they call “matrix inverse targeting” (MINT). Instead of binding to a specific molecular marker, MINT nanoparticles exploit a natural biochemical shift that occurs as cartilage deteriorates. Healthy cartilage is rich in glycosaminoglycans (GAGs), molecules that give the tissue a strong negative charge. As OA progresses and GAGs are lost, the tissue becomes less negatively charged. The nanoparticles are designed to be repelled by healthy, GAG-rich cartilage and drawn into regions where GAG loss has occurred—effectively using the disease itself as the targeting signal.
Because GAG loss increases with disease severity, the system automatically delivers more nanoparticles to more severely damaged areas. This “precision entry” mechanism allowed the researchers to deliver mRNA encoding ghrelin, a protein with known chondroprotective properties. In preclinical mouse OA models, ghrelin mRNA-loaded MINT nanoparticles reduced cartilage degeneration, limited subchondral bone thickening, lowered inflammatory signaling, and decreased activation of pain-related nerve pathways.
The findings address a major gap in OA therapeutics: existing delivery systems cannot distinguish between healthy and damaged cartilage, often diluting treatment across the joint. By contrast, the MINT platform concentrates therapy exactly where it is needed—and adapts as the disease evolves.
The implications may extend beyond osteoarthritis. Because the targeting mechanism relies on universal biochemical changes rather than engineered ligands, the approach could be applied to a wide range of RNA therapies and potentially to other diseases characterized by matrix degradation.
Next steps include extending the duration of therapeutic effects, demonstrating compatibility with additional RNA cargos, and testing the platform in larger preclinical models that more closely mimic human knee joints. These studies will help determine how soon this technology could move toward clinical translation.
For a disease long defined by limited treatment options, the ability to deliver gene therapy directly into the heart of cartilage damage represents a striking leap forward—and a glimpse of what disease-responsive medicine could look like in the years ahead.
